07 October 2019

Sensyne Health Maiden Full Year Results

 

Oxford, UK; 7 October 2019: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the British Clinical AI technology company, today announces its audited full year results for the 12 months ended 30 April 2019.

Lord (Paul) Drayson, CEO of Sensyne Health, commented: “I am pleased to report strong progress in our first full year reporting period as a public company, achieving a number of important milestones.”

OPERATING HIGHLIGHTS (INCLUDING POST-PERIOD EVENTS)

  • First major pharmaceutical collaboration agreement for £5m signed with Bayer to accelerate the development of new treatments for cardiovascular disease using Clinical Artificial Intelligence

 

  • Signed agreements with a Fortune 200 company and a data infrastructure specialist to launch and scale our digital health products in the U.S. – see separate press release issued today

 

  • New partnership created with Evotec, Oxford University Innovation, Oxford Sciences Innovation and the University of Oxford called LAB10x to accelerate the commercialisation of the next generation of digital therapeutics and data-driven drug discovery from clinical artificial intelligence research and digital health innovations

 

  • Signing of an agreement with Jefferson Health for the clinical and economic evaluation of Sensyne Health’s GDm-Health™ digital therapeutic product and generation of curated patient data within a US hospital system

 

  • Strategic Research Agreement (SRA)s with two further NHS Trusts: George Eliot NHS Trust and Wye Valley NHS Trust

 

  • The number of unique patients represented in the data held by NHS partner trusts stands at 2,105,000

 

  • 20,057,000 patient admissions represented in the data held by NHS partner trusts

 

  • Entered into a formal research agreement with the UK MHRA (Medicines and Healthcare products Regulatory Agency) to contribute to the development of methods to validate software algorithms used in digital health – see separate press release issued today

 

FINANCIAL HIGHLIGHTS

  • Total revenues of £0.136m for the year to 30 April 2019 (2018: £0.081m)
  • Research and development expenditure of £9.512m (2018: £2.742m)*
  • Adjusted operating loss from continuing operations of £11.513m (2018: £6.222m)
  • Operating loss of £19.010m for the year to 30 April 2019 (2018: £7.253m)
  • Adjusted cash used in operations of £9.779m (2018: £5.372m)
  • Cash and cash equivalents of £49.252m at 30 April 2019(2018: £4.541m)
  • Adjusted loss per share of £0.10 (2018: £0.06)

           

*Incurred or capitalised net of amortisation, excluding SRAs 

 

Analyst and Investor briefing

Lord Drayson, Chief Executive Officer, and Lorimer Headley, Chief Financial Officer, will present the full year results for analysts and investors today at 12.00 BST. There will be a simultaneous live conference call and webcast. For more details please contact radu@consilium-comms.com at Consilium Strategic Communications.

 

A replay of today’s webcast of the meeting and the presentation slides will be available on the investor section of Sensyne Health’s website after the event at https://www.sensynehealth.com/investors/investor-hub

 

 

 

 

 

 

 

 

For more information please contact:

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng, Chief Executive Officer

 

Lorimer Headley, Chief Financial Officer

 

 

 

 

Peel Hunt LLP (Nominated Adviser and Broker)

 

+ 44 (0) 20 7418 8900

Dr Christopher Golden

 

James Steel

 

Oliver Jackson

 

Consilium Strategic Communications

+44 (0) 20 3709 5700

Mary-Jane Elliott

 

Sukaina Virji

 

Melissa Gardiner

 

sensynehealth@consilium-comms.com

 

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com


Back to previous page